June 16 2016  

 

 

Highlights from EAS 2016 Innsbruck!

We thank everyone participating in EAS 2016 Innsbruck for contributing to the meeting’s success! More than 2000 delegates attended the meeting, arriving from 79 countries, and five continents.

Below you will find some of the topics from the sessions being discussed in interviews with the speakers, including a summary from Professor Kostner of the Satellite meeting on Lp(a) held in Innsbruck prior to the EAS congress.

Check the Congress website and EAS news for the daily session reports and interviews with the faculty during the congress.

EAS 2016 Innsbruck, session reports >>
News from the EAS congress (reports and interviews) >>

From EAS-ESC Joint Workshop: Sex differences in cardiovascular disease

Prof. Borge Nordestgaard discusses the content presented during the joint EAS-ESC workshop held on Monday May 30 on the evidence for sex differences in biomarkers and risk factors for CVD.

To the interview >> 

EAS EFLM consensus paper on fasting vs. nonfasting lipid testing

Should lipid testing be performed under fasting or nonfasting conditions – what is the evidence?

A recent joint consensus statement from the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) has scrutinised the evidence and concluded that fasting is not routinely required for determination of a lipid profile. At EAS Congress, Professor Borge Nordestgaard (University of Copenhagen, Denmark) discusses this consensus paper.

To the interview >>

Looking back at the Lipoprotein(a) Satellite meeting

Gerhard Kostner, Emeritus Full Professor of Biochemistry and Molecular Biology at the Medical University of Graz, Austria looks back at the Lipoprotein(a) Satellite Meeting of the European Atherosclerosis Society Congress: From Bench to Bedside, Innsbruck 27-29 May, 2016.

Fifty years since first reported by Kåre Berg, Oslo, Norway, lipoprotein(a) is now accepted as a causal risk factor for atherosclerotic cardiovascular disease. Despite this, this Satellite Meeting showed that gaps in knowledge about lipoprotein(a) remain. These include uncertainties in analysis, biosynthesis and catabolism, and most importantly, the key question: What makes lipoprotein(a) so atherogenic?

To the interview >>



     
 
Find out more

About this email


 

European Atherosclerosis Society © 2015



This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@